Findings
========

Background
----------

Reduced insulin sensitivity is a predictor of incident type 2 diabetes and atherosclerotic risk \[[@B1]\]. The hyperinsulinemic euglycemic clamp (HEC) is considered the gold standard *in vivo* measurement of insulin sensitivity by calculating whole body glucose disposal (M). As the clamp is carried out under hyperinsulinemic conditions, hepatic glucose output is generally suppressed \[[@B2]\] and thus M mostly represents peripheral insulin sensitivity. The frequently sampled intravenous glucose tolerance test (FSIVGTT) measures whole body insulin sensitivity through the calculation of the insulin sensitivity index (S~I~) \[[@B3]\]. As both these measures are complex, the homeostatic model assessment of insulin resistance (HOMA-IR) is one of the most frequently used methods of determining insulin resistance in large population based studies, since it is mathematically derived from single fasting glucose and insulin measurements.

HOMA-IR has been used to assess longitudinal changes in insulin resistance in persons with type 2 diabetes of various ethnic groups in order to examine the natural history of diabetes and to assess the effects of treatment \[[@B4]\]. It can also be utilized in non-diabetic populations as it allows *1*) comparisons of insulin sensitivity among persons with abnormal glucose tolerance and *2*) the longitudinal assessment of persons who later develop abnormal glucose tolerance \[[@B4]\]. HOMA-IR has been validated against the HEC in multiple studies across several populations (r = 0.5-0.8) \[[@B5]\]. Other indices that utilize fasting glucose and insulin data (e.g. quantitative insulin sensitivity check index, QUICKI) have questionable superiority to HOMA \[[@B6],[@B7]\].

Afro-Caribbean adults have high rates of type 2 diabetes and the metabolic syndrome, but there has been no validation of these simple measures of insulin resistance in this population. Consequently, we compared a simple surrogate measure of insulin resistance/sensitivity, HOMA-IR to measures derived from HEC and FSIVGTT in 110 non-diabetic Afro-Caribbean adults.

Methods
-------

### Study design

These data were derived from two observational studies that utilized either a clamp or a FSIVGTT in 110 non-diabetic Jamaican adults. Diabetes was excluded on the basis of the patient's stated history, a normal fasting plasma glucose, as well as an oral glucose tolerance test. In both studies, we excluded persons who were pregnant, had renal impairment, used glucocorticoids or smoked. None of the participants were taking drugs that affect insulin action, viz. insulin sensitizers, hypolipidemic agents, oral contraceptives or anabolic steroids. We also measured anthropometry using a standardized protocol \[[@B8]\] and body fat using dual energy x-ray absorptiometry.

The Faculty of Medical Sciences/University Hospital of the West Indies Ethics Committee approved the protocols and all participants gave written informed consent.

### Data collection

In the first study \[[@B9]\], we recruited 60 participants age 22--23 years old from the Jamaican Birth Cohort. A modified FSIVGTT was performed in the morning after a 10 hour fast. After securing intravenous access in the right antecubital vein, a 0.3 g/kg bolus of 50% dextrose was given over 1 minute at time zero. At 20 minutes, 0.03 IU insulin per kg body weight was injected into the right antecubital vein. Blood was collected at −10, −5, 0, 2, 3, 4, 5, 6, 8, 10 12, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140 and 180 minutes to measure plasma glucose and insulin concentrations. Glucose was measured using glucose oxidase assay and plasma insulin measured with an enzyme-linked assay (Immulite®, DPC, LA, CA). The assay had an analytical sensitivity of 2 μIU/ml and the intra-assay coefficient of variation (CV) was \< 8%. The MINMOD Millennium 6.02 software (MINMOD Inc., Pasadena, CA, USA) was used to calculate S~I~.

We performed 150-minute hyperinsulinemic euglycemic clamps in another study of 50 non-diabetic adults \[[@B10]\]. This included 40 survivors of childhood malnutrition and 10 age, sex and BMI-matched community controls who were never exposed to malnutrition. The studies were conducted in the morning after a 10 hour overnight fast. We inserted a retrograde intravenous cannula into a right dorsal metacarpal vein, and then the right hand was placed in a warm box maintained at 50°C to arterialize venous blood for intermittent sampling. Insulin was infused into a left antecubital vein at a rate of 1 mIU/kg/min and blood glucose was clamped at 5 mmol/l by means of a variable rate infusion of 20% dextrose water. During the procedure, plasma glucose concentrations were measured every 5 minutes from the right cannula with a glucose analyzer (YSI Instruments, Yellow Springs, OH). Additionally, blood was collected every 10 minutes in a fluoridinated tube to measure glucose and a heparinised tube to measure insulin levels. Glucose was measured in the laboratory using glucose oxidase and plasma insulin measured using an immunoassay technique (ALPCO, Salem, NH). The intra-assay coefficient of variation was 3.13%.

The whole-body glucose disposal rate (M) was calculated as the mean of the glucose infusion rate during steady state of the clamp as follows:

*M* = *GIR* − *SC*;   where GIR was the glucose infusion rate and SC the space correction.

SC (mg/kg/min) = (G~2~-G~1~) × 0.63.

The steady state was defined as a 30 minute period occurring after 120 minutes, during which the coefficients of variation for blood glucose and GIR were less than 5% \[[@B11]\].

For all 110 participants, HOMA-IR was calculated as follows \[[@B12]\]:

$$\mathit{HOMA} - \mathit{IR} = \frac{{fasting}\ {insulin}\ \left( \mathbf{uIU}/\mathbf{ml} \right)\ \times\ {Fasting}\ {glucose}\ \left( \frac{mmol}{L} \right)}{22.5}$$

In our laboratory, the correlation between the insulin assays used in both studies was 0.9.

### Statistics

Continuous variables are presented as means ± SDs and in highly skewed data we used medians with interquartile ranges. HOMA-IR, S~I~ and M were log transformed to a normal distribution before the use of parametric tests. Comparisons of means were assessed using 2 sample *t*-test. Partial correlation coefficients were used to explore the associations between HOMA-IR with M and S~I~, controlling for age and sex. Statistical analyses were performed using SPSS 16.0 (SPSS, Chicago, IL). *P*-values ≤ 0.05 were considered statistically significant.

Results
-------

The clinical characteristics of our study populations are shown in the Table [1](#T1){ref-type="table"}. The two groups did not differ with respect to age or adiposity but the HEC group was more insulin resistant using HOMA-IR (p \< 0.0001).

###### 

Clinical and metabolic characteristics of Afro-Caribbean adults who had FSIVGTT or HEC

  **Characteristics**                          **FSIVGTT**         **HEC**                                
  -------------------------------------------- ------------------- ------------------- ------------------ -----------------
  **Age (years)**                              23.1 ± 0.5          23.1 ± 0.5          27.6 ± 9.1         27.0 ± 7.4
  **Height (cm)**                              177.0 ± 5.5         164.8 ± 7.2         171.7 ± 7.8        158.7 ± 7.1
  **Weight (kg)**                              73.4 ± 12.0         72.9 ± 25.3         69.0 ± 12.6        60.3 ± 16.2
  **BMI (kg/m**^**2**^**)**                    23.4 ± 3.4          26.6 ± 8.4          22.3 ± 3.8         23.8 ± 5.8
  **Waist (cm)**                               77.4 ± 8.1          81.4 ± 16.8         78.1 ± 9.9         75.7 ± 14.5
  **Percent body fat (%)**                     14.6 ± 8.8          37.7 ± 11.6         13.7 ± 8.7         33.3 ±11.4
  **Fasting glucose (mmol/l) l/L**             5.1 ± 0.3           4.9 ± 0.4           4.1 ± 0.7          4.3 ± 0.5
  **Fasting insulin (uIU/ml)**                 2.0 (2.0, 2.0)      2.0 (2.0, 5.2)      10.4 (3.0, 17.6)   8.0 (4.5, 14.6)
  **M (mg.kg**^**-1**^**.min**^**-1**^**)**    \-                  \-                  9.0 (5.9,12.1)     7.3 (5.2, 10.2)
  **S**~**I**~**\[min**^**-1**^**(μU/ml)\]**   2.2 (1.3, 3.4)      1.9 (0.6, 2.8)      \-                 \-
  **HOMA-IR**                                  0.44 (0.42, 0.52)   0.44 (0.40, 1.65)   1.6 (0.7, 3.0)     1.6 (0.9, 2.5)

### FSIVGTT

The participants were 55% male, age 23.1 ± 0.1 years and BMI 24.8 ± 6.3 kg/m^2^. HOMA-IR did not correlate with S~I~ (Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"}) even after further adjustment for BMI (r = 0.16, *p* = 0.25). However, HOMA-IR had significant positive associations with weight, BMI, waist circumference and % body fat. S~I~ had negative associations with weight, BMI, waist and % body fat (Table [2](#T2){ref-type="table"}).

###### 

Correlations (r) of clinical and metabolic characteristics with measures of insulin sensitivity in Afro-Caribbean adults

  **Measurement**                              **FSIVGTT (55% male) N = 60**   **HEC (44% male) N = 50**            
  -------------------------------------------- ------------------------------- --------------------------- -------- ---------
  **Age (years)**                              −0.08                           0.05                        −0.14    −0.18
  **Height (cm)**                              0.23                            0.03                        −0.11    −0.02
  **Weight (kg)**                              0.39^**\***^                    −0.34^**\***^               0.01     −0.32\*
  **BMI (kg/m**^**2**^**)**                    0.36^**\***^                    −0.38^**\***^               0.08     −0.33\*
  **Waist (cm)**                               0.39^**\***^                    −0.39^**\***^               0.06     −0.50\*
  **Percent body fat (%)**                     0.29^**\***^                    −0.40^**\***^               0.10     −0.49\*
  **F glucose (mmol/l) l/L**                   0.45^**\***^                    0.08                        0.07     −0.16
  **F insulin (uIU/ml)**                       0.99^**\***^                    −0.02                       0.99\*   −0.16
  **M (mg.kg**^**-1**^**.min**^**-1**^**)**    \-                              \-                          −0.18    1.00\*
  **S**~**I**~**\[min**^**-1**^**(μU/ml)\]**   −0.01                           1.00^**\***^                \-       \-
  **HOMA-IR**                                  1.00^**\***^                    −0.01                       1.00\*   −0.18

Correlations are adjusted for age and sex; those that are statistically significant at the 5% level are shown with an asterisk.

![**Correlations between HOMA-IR and S**~**I**~**in non-diabetic Afro-Caribbean adults (r = −0.14,*P*** **= 0.19).**](1756-0500-7-98-1){#F1}

### HEC

The participants were 44% male, age 27.3 ± 8.1 years and BMI 23.6 ± 5.0 kg/m^2^. There was no significant correlation between HOMA-IR and M (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}) even after adjusting for BMI (r = −0.17, *p* = 0.26). Additionally, no association between HOMA-IR and M was found in a subgroup of 7 individuals that were diagnosed for the first time with pre-diabetes during the study (r = −0.54; *P* = 0.22). M had significant negative associations with weight, BMI, waist and % body fat (*P*-values ≤ 0.04).

![**Correlations between HOMA-IR and M in non-diabetic Afro-Caribbean adults (r = −0.01,*P*** **= 0.93).**](1756-0500-7-98-2){#F2}

Discussion
----------

Fasting indices of insulin sensitivity compare poorly with estimates derived from HEC and FSIVGTT in our study population. While our findings contrast with data from other populations, they were consistent with the findings from studies in elderly diabetic Japanese and Greek women with polycystic ovary syndrome \[[@B13]\]. Pisprasert et al. concluded more recently that insulin sensitivity indices based on fasting glucose and insulin levels should be used cautiously as measures of peripheral insulin sensitivity when comparing mixed gender and mixed race populations \[[@B14]\]. Although our sample size was comparatively small, other studies that validated dynamic measures and HOMA-IR typically used 25--60 participants which is similar in size to our study \[[@B12]\].

There may be several factors that explain this apparent inconsistency. First, African-Americans secrete more insulin at any given level of insulin sensitivity \[[@B15]\] and their rates of insulin clearance may be lower than Caucasians \[[@B16]\]. Therefore in this population, fasting indices may overestimate insulin resistance. This would also produce stronger correlations in populations that are more insulin resistant and/or diabetic as opposed to our participants who were more insulin sensitive. While early beta cell failure could also alter fasting indices, this is unlikely to be the factor as African Americans have greater beta cell function compared to Caucasians \[[@B17]\].

Additionally, insulin resistance is a heterogeneous entity, that is, it impairs glucose uptake in several tissues especially muscle and adipose tissues, as well as it affects hepatic glucose output. Individuals may have varying phenotypes of insulin resistance and, therefore, the calculated indices may not completely reflect the *in vivo* milieu \[[@B13]\]. Consequently, one possible explanation for the lack of association in our population is a difference in impaired peripheral insulin action compared to hepatic insulin action. HOMA-IR and QUICKI are based on the feedback loop of glucose and insulin in the post-absorptive state and thus are more representative of hepatic insulin resistance and hepatic glucose output. Interestingly, in pre-pubertal and early pubertal adolescents, HOMA and fasting insulin were shown to reflect total body insulin sensitivity and hepatic insulin resistance, but not peripheral insulin sensitivity \[[@B18]\]. This is contrary to hyperinsulinemic clamps performed at steady-state serum insulin levels that suppress hepatic glucose production and directly reflect glucose disposal predominantly into skeletal muscle. On the other hand, the FSIVGTT combines the effects of insulin to promote glucose disposal in skeletal muscle and suppress hepatic glucose production \[[@B19]\]. As a result, fasting indices may correlate poorly with S~I~ and M in persons who mostly have peripheral insulin resistance. Afro-Americans have significant hepatic insulin resistance compared to peripheral insulin sensitivity \[[@B20]\]. This is so despite African Americans having less hepatic fat compared with Hispanics and Caucasians \[[@B20]\]. Whole body insulin resistance may therefore equate to a different, but overlapping set of metabolic derangements and may reflect tissue-specific differences in insulin signaling \[[@B20]\].

Another factor that may have influenced our findings is our relatively lean population. Fasting indices have been shown to be less accurate in subjects with normal or near normal weight \[[@B21]\]. The degree of obesity modifies the relationships among insulin resistance, insulin secretion and insulin catabolism such that plasma glucose and insulin concentrations are better able to delineate differences in more obese individuals \[[@B21]\]. Of note, however, was the observation that HOMA-IR did correlate with clinical measures of insulin resistance (i.e. adiposity) similar to S~I~ and M.

Conclusion
----------

In this first study exclusively investigating young, Afro-Caribbean adults, we showed that fasting indices are not equivalent to indices derived from the FSIVGTT or HEC. Our findings, however, may have been influenced by the fact that this population was lean and relatively insulin sensitive. Fasting indices may therefore be less reliable at predicting insulin sensitivity in this group, and, by extension, in studies involving multiple ethnic groups. In spite of this, fasting indices may still prove to be useful as a ranking tool in epidemiological studies in this population.
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